Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension

Aim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years,...

Full description

Bibliographic Details
Main Authors: Ivan Petrovich Gorshkov, Vladimir Ivanovich Zoloedov, Anna Petrovna Volynkina
Format: Article
Language:English
Published: Endocrinology Research Centre 2010-06-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/5680
_version_ 1797255280295149568
author Ivan Petrovich Gorshkov
Vladimir Ivanovich Zoloedov
Anna Petrovna Volynkina
author_facet Ivan Petrovich Gorshkov
Vladimir Ivanovich Zoloedov
Anna Petrovna Volynkina
author_sort Ivan Petrovich Gorshkov
collection DOAJ
description Aim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied. Results. The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.
first_indexed 2024-03-08T15:22:22Z
format Article
id doaj.art-69d066b79e9944b6b870f0143f223c9f
institution Directory Open Access Journal
issn 2072-0351
2072-0378
language English
last_indexed 2024-04-24T22:03:20Z
publishDate 2010-06-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj.art-69d066b79e9944b6b870f0143f223c9f2024-03-20T11:47:55ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782010-06-01132848910.14341/2072-0351-56805638Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertensionIvan Petrovich Gorshkov0Vladimir Ivanovich Zoloedov1Anna Petrovna Volynkina2Voronezh State Medical Academy named by N.N. Burdenko, VoronezhVoronezh State Medical Academy named by N.N. Burdenko, VoronezhVoronezh State Medical Academy named by N.N. Burdenko, VoronezhAim. To study Actovegin efficacy in oxidative stress (OS) correction at diabetic polyneuropathy (DPN) in patients with diabetes mellitus type 2 (DM2)and arterial hypertension (AH).Materials and Methods. 51 patients (24 women and 27 men) aged 53.4?0.7 with the average duration of DM2 5.6?0.2 years, DPN - 4.9?0.2years and AH - 6.0?0.2 years were examined. Daily albuminuria, glomerular filtration rate (GRF) were evaluated, standard methods for diagnosisof DPN were used. 26 patients took Actovegin therapy during 6-8 weeks, the rest 25 patients were in the control group. Parameters of the OS werestudied. Results. The increase of total oxidative capacity, the decrease of total antioxidant capacity and the rise of levels of antibodies to oxidated LDL wererevealed in patients with DM2, DPN and AH. Antioxidant and anti-hypoxic effects of 400 mg/day of Actovegin were established in this group of patients.Conclusions. Actovegin impacts oxidative stress parameters and improves the clinical manifestation of diabetic polyneuropathy.https://www.dia-endojournals.ru/jour/article/view/5680diabetic polyneuropathylipid peroxidationactoveginoxidative stressdiabetes mellitus
spellingShingle Ivan Petrovich Gorshkov
Vladimir Ivanovich Zoloedov
Anna Petrovna Volynkina
Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
Сахарный диабет
diabetic polyneuropathy
lipid peroxidation
actovegin
oxidative stress
diabetes mellitus
title Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_full Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_fullStr Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_full_unstemmed Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_short Clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
title_sort clinical efficacy of oxidative stress correction by actovegin in diabetic polyneuropathy at type 2 diabetic patients with arterial hypertension
topic diabetic polyneuropathy
lipid peroxidation
actovegin
oxidative stress
diabetes mellitus
url https://www.dia-endojournals.ru/jour/article/view/5680
work_keys_str_mv AT ivanpetrovichgorshkov clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension
AT vladimirivanovichzoloedov clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension
AT annapetrovnavolynkina clinicalefficacyofoxidativestresscorrectionbyactoveginindiabeticpolyneuropathyattype2diabeticpatientswitharterialhypertension